Claims for Patent: 9,061,042

Summary for Patent: 9,061,042

Title:	Composition for suppressing expression of target gene
Abstract:	An object of the present invention is to provide a composition for suppressing expression of a target gene, and the like. A composition comprising an RNA-encapsulated liposome, wherein the RNA contains a sequence consisting of 15 to 30 contiguous bases of a target gene mRNA (hereinafter, sequence X) and a base sequence (hereinafter, complementary sequence X′) complementary to the sequence X, 1 to 90% of all sugars binding to the bases of the sequence X and the complementary sequence X′ being ribose substituted by a modifying group at 2′ position, and the lipid particle being capable of reaching a tissue or an organ containing an expression site of the target gene is provide.
Inventor(s):	Nobuhiro Yagi, Junichi Enokizono
Assignee:	Kyowa Kirin Co Ltd
Application Number:	US13/017,562

Details for Patent 9,061,042

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kamada Ltd.	VARIZIG	varicella zoster immune globulin (human)	For Injection	125430	December 20, 2012		2031-01-31
Kamada Ltd.	VARIZIG	varicella zoster immune globulin (human)	Injection	125430	September 29, 2014		2031-01-31

International Patent Family for US Patent 9,061,042

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2010013815
United States of America	2011182980
South Korea	20110042294
South Korea	101630888
Japan	WO2010013815